SPOTLIGHT -
EP. 1: Dr. Spring on the Rationale for the AMEERA-1 Trial in ER+/HER2- Advanced Breast Cancer
Laura Spring, MD, discusses the rationale for the ongoing phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
